Neurode Unveils Novel Wearable Headband to Treat and Track ADHD Symptoms

Neurode Unveils Novel Wearable Headband to Treat and Track ADHD Symptoms

Facebook
Twitter
LinkedIn

Sydney-based medical technology company Neurode has developed a novel wearable headband to offer relief to people living with attention deficit hyperactivity disorder (ADHD), which affects about 366 million adults across the globe.

According to Nathalie Gouailhardou, a neuroscientist and founder of Neurode, the device offers a non-invasive treatment alternative that requires only a few minutes of daily therapy sessions without facing the side effects associated with the use of pharmaceutical drugs.

Neurode Unveils Novel Wearable Headband to Treat and Track ADHD Symptoms
Neurodes ADHD Tracking and Treating Device

Designed to be worn for only 20 minutes per day, the wearable headband employs light electrical stimulation in the prefrontal cortex to induce a balance in the brain, helping treat some of the common symptoms of ADHD, such as lack of focus.

The wearable device uses light to monitor brain changes and record activities, helping to monitor ADHD. Due to the electrical signals sent into the brain, some people reported a tingling sensation, while others felt no notable side effect of the therapy. The stimulation ramps up over time with a continued use of the headband.

Gouailhardou founded Neurode in 2021 to provide a simple and cost-effective treatment for ADHD patients, inspired by personal experiences. The company filed patents for the novel technology the same year and later secured $3.5 million in seed capital from Khosla Ventures and PsyMed Ventures for clinical trials.

She told Tech Crunch that Neurode employs a unique approach to treating ADHD, which could be extended to track other mental health conditions, such as depression and Age-related cognitive decline.

The wearable device is available via a private beta, with the company working on US regulatory requirements to get the device approved by the US Food and Drug Administration (FDA) in the future.